Abstract: The present application relates to recombinant microorganisms useful in the biosynthesis of monoethylene glycol (MEG) or glycolic acid (GA), or MEG and one or more co-product, from one or more pentose and/or hexose sugars. Also provided are methods of producing MEG (or GA), or MEG (or GA) and one or more co-product, from one or more pentose and/or hexose sugars using the recombinant microorganisms, as well as compositions comprising the recombinant microorganisms and/or the products MEG (or GA), or MEG and one or more co-product.

Abstract: Variant guinea pig L-asparaginases which are truncated and humanized are described as are fusion proteins containing the L-asparaginase and use of the L-asparaginases in the treatment of cancers such as acute lymphoblastic leukemia and acute myeloid leukemia.

Abstract: Provided is a method for producing an organic substance from a syngas by microbial fermentation, wherein only the solid component can be efficiently separated from an organic substance-containing liquid obtained by microbial fermentation to reduce the content of microorganisms, etc. Disclosed is a method for producing an organic substance from a syngas containing carbon monoxide by microbial fermentation, which comprises a microbial fermentation step wherein the syngas is fed to a microbial fermenting vessel and a liquid containing an organic substance is obtained by microbial fermentation, a solid-liquid separation step wherein the organic substance-containing liquid is separated into a solid component containing microorganisms and a liquid component containing an organic substance, and an extraction step wherein the organic substance-containing liquid is extracted from the liquid component, wherein the organic substance-containing liquid is heated to 40° C.

Abstract: Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.

Abstract: Disclosed herein are glucosyltransferases with modified amino acid sequences. Such engineered enzymes exhibit improved alpha-glucan product yields and/or lower leucrose yields, for example. Further disclosed are reactions and methods in which engineered glucosyltransferases are used to produce alpha-glucan.

Abstract: An object of the present invention is to provide an enzyme showing random transesterification ability, which is suitable for food applications. Provided is a random transesterification lipase having high heat resistance in oils and fats.

Abstract: The present disclosure provides the sequence of a Paenibacillus polymyxa preproenzyme which is the precursor of a neutral protease, expression thereof in a transformed host organism, and methods for production of the neutral protease, by recombinant means. Further, use of the recombinantly produced neutral protease is disclosed in the field of cell biology, particularly for the purpose of tissue dissociation. The disclosure also includes blends with other proteases. Further disclosed are nucleotide sequences encoding the neutral protease.

Abstract: Disclosed herein are methods for N-demethylating an N-methylated compound using an enzymatic reaction, rather than, e.g. a chemical modification. Also provided herein are enzymes for performing the reaction.

Abstract: The invention relates to the field of nutritional ingredients, in particular to methods for producing hypoallergenic galacto-oligosaccharides (GOS) and the use thereof in food and drink items. Provided is the use of a beta-galactosidase (EC 3.2.1.23) derived from Cryptococcus terrestris (recently renamed Papiliotrema terrestris) in the production of a hypoallergenic GOS preparation having a reduced capacity to induce an allergic response in a subject.

Abstract: Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.

Abstract: The present disclosure relates to biological processes and systems for the production of isopropanol and/or acetone utilizing modified alcohol dehydrogenases that exhibit increased activity with NADH as a cofactor. The disclosure further relates to polynucleotides and polypeptides of the modified alcohol dehydrogenases, and host cells containing the polynucleotides and expressing the polypeptides.

Abstract: The present invention relates to polypeptides, nucleotides encoding the polypeptide, as well as methods of producing the polypeptides. The present invention also relates to detergent composition comprising polypeptides, a laundering method and the use of polypeptides.

Abstract: The present disclosure relates to a protein variant having a tryptophan-exporting activity, an L-tryptophan-producing microorganism expressing the protein variant, and a method for producing L-tryptophan using the microorganism.

Abstract: The present invention provides methods and compositions for increasing lignin degradation to produce a biological product. Also provided are methods for increasing expression of laccase in a bacterial species to produce increased lignin degradation. Also provided are bacterial cells and commodities or commodity produces produced from such methods.

Abstract: The present invention relates to a polypeptide having lipolytic enzyme activity, selected from the group consisting of: (a) a polypeptide having at least 65% sequence identity to amino acids 21 to 309 of SEQ ID NO: 1; (b) a polypeptide encoded by a polynucleotide that hybridizes under medium stringency conditions with the polypeptide coding sequence of SEQ ID NO: 2; (c) a polypeptide encoded by a polynucleotide having at least 65% sequence identity to the polypeptide coding sequence of SEQ ID NO: 2; and (d) a fragment of the polypeptide of (a), (b) or (c) that has lipolytic enzyme activity.

Abstract: Method of preparing a keratin-based biomaterial is provided. The method comprises a) reacting keratin with a polymer having at least one of an amine and carboxylic functional group in the presence of a carbodiimide cross-linking agent to form a cross-linked keratin-polymer material; and b) freeze drying the cross-linked keratin-polymer material to form the keratin-based bio-material. A keratin-based biomaterial thus prepared is also provided.

Abstract: Disclosed herein is an endotoxin-free asparaginase enzyme. Also disclosed are methods of using the disclosed enzyme to treat subjects with a disease treatable by depletion of asparagine. For example, the disclosed endotoxin-free asparaginase enzyme is useful in the treatment or the manufacture of a medicament for use in the treatment of acute lymphoblastic leukemia (ALL) in both adults and children, as well as other conditions where asparagine depletion is expected to have a useful effect.

Abstract: A polypeptide includes, in the amino acid sequence of SEQ ID NO: 1 or a similar sequence, at least one specific amino acid substitution on at least one of the 14th, 37th, 209th, 293rd, and 319th amino acid residues from the N-terminal of the amino acid sequence of SEQ ID NO: 1. A polynucleotide, an expression cassette, a vector, and a transformant include a base sequence encoding the amino acid sequence of the polypeptide. A method of producing the polypeptide and a method of producing 2-deoxy-scyllo-inosose are also provided.

Abstract: The present invention relates to compositions such as cleaning compositions comprising a mix of enzymes. The invention further relates, use of compositions comprising such enzymes in cleaning processes.

Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.